Wyeth, Cordis Stent Patents Are Invalid, Fed. Circ. Rules

Law360, New York (June 26, 2013, 3:46 PM EDT) -- The Federal Circuit on Wednesday affirmed a lower court's ruling that two Cordis Corp. and Wyeth Pharmaceuticals Inc. patents covering a drug used in stents are invalid, in a win for Abbott Laboratories and other competitors accused of infringement.

A three-judge panel held that the patents covering the use of rapamycin to prevent the narrowing of an artery are invalid for lack of enablement because one skilled in the art could not practice the full scope of the patents without undue experimentation.

"There is no genuine...
To view the full article, register now.